Insilico Medicine
About Insilico Medicine
Insilico Medicine leverages generative artificial intelligence and automation to accelerate drug discovery and aging-related research from discovery through development. The company operates globally with facilities in Boston, Hong Kong, Abu Dhabi, and Shanghai, focusing on AI-driven biology, target identification, and therapeutic program development through its Pharma.ai suite and science platforms like PandaOmics, Chemistry42, Generative Biologics, and inClinico. Its mission is to extend healthy longevity and sustainability by reducing time and cost to bring life-saving medications to patients. The company emphasizes multidisciplinary collaboration across biotechnology, computational biology, and translational medicine to create novel therapeutics.
Recent News
Biotech’s IPO Comeback; Trump’s Tariff Loophole for Pharma
Servier Signs €1bn-Plus AI Pact with Iktos
Insilico Medicine Welcomes Dr. Halle Zhang as New Vice President of Clinical Development for Oncology
Insilico’s Big Gain After Hong Kong Listing: Finance Report
STAT+: Insilico Medicine CEO on How Best to Use AI in Drug Development
Swiss Study Finds 37‑Protein Signature That Sets Centenarians Apart
Top Biotech Deals in March 2026
China Investors Energise Hong Kong Biotech Stocks. Is Foreign Money Missing Out?
Ex-CEO Behind Bars, 10x’s Clinical Ambitions, Pharma’s AI Gambit
AI Giant Anthropic Leans Into Life Sciences With $400M Coefficient Bio Catch
AI Drug Discovery Is Reshaping Longevity Medicine. Is Your Practice Ready?
Insilico Medicine Launches Pharma AI Spring Kickoff 2026 Webinar
How AI Is Helping Solve the Labor Issue in Treating Rare Diseases
STAT+: Lilly’s Obesity Pill Enters the Oral GLP-1 Game, Novo Responds
Jurassic Bag: From Dinosaur DNA to Designer Goods – How Biofabrication and Automation Could Reshape Materials
Lilly Wants to Bridge Cancer Care Gap with $300M ADC Biotech Buy
AI Can Screen 15 Million Molecules in a Day. It Still Can’t Cure Alzheimer’s.
December 2025 Patent Highlights
From Prompt to Pill: Researchers Propose AI-Driven Path To ‘Pharmaceutical Superintelligence’
Insilico Medicine and CMS Forge Multiple Collaborations to Accelerate AI-Driven R&D in CNS and Autoimmune Disorders
Insilico’s Latest Deal Is a $120M Cardiometabolic Drug Discovery Pact with Qilu Pharma
